Digestive Diseases and Sciences

, Volume 56, Issue 12, pp 3638–3647 | Cite as

Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis

  • Shin Yasui
  • Keiichi Fujiwara
  • Akinobu Tawada
  • Yoshihiro Fukuda
  • Masayuki Nakano
  • Osamu Yokosuka
Original Article



Acute onset autoimmune hepatitis (AIH) shows acute presentation like acute hepatitis and does not have typical clinicopathological features of AIH. There is no gold standard for making the diagnosis. Therefore, losing the timing of starting immunosuppressive therapy, some of the cases develop into severe or fulminant form and have poor prognosis.


Our aim was to elucidate the efficacy of intravenous glycyrrhizin in decreasing alanine aminotransferase (ALT) level in the early stage of acute onset AIH.


Thirty-one patients were defined as acute onset AIH based on our uniform criteria, and were enrolled in this study. We prospectively treated 17 patients with sufficient doses (100 ml/day) of intravenous glycyrrhizin (SNMC) at an early stage (SNMC group), and treated 14 patients of severe disease with intravenous glycyrrhizin and corticosteroids (CS) (SNMC + CS group). We examined their clinical and biochemical features and treatment responses.


The ALT level could be controlled at an early stage using SNMC with no significant difference compared with SNMC + CS, and responsiveness to the therapy was determined by the disease severity at the time of starting therapy rather than the time duration from onset to therapy. Recovery rate was higher in the SNMC group than in the SNMC + CS group (P = 0.035).


The early introduction of sufficient doses of SNMC might prevent disease progression in patients with acute onset AIH. SNMC can be used safely and be useful for patients with difficult-to-diagnose acute liver disease as an ‘initial’ treatment tool to improve liver inflammation before starting disease-specific treatments.


Autoimmune hepatitis Acute onset Intravenous glycyrrhizin Disease severity 



Autoimmune hepatitis


Stronger Neo-Minophagen C





We are indebted to all our colleagues at the liver units of our hospitals who cared for the patients described here. This study was supported in part by a Health Labour Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan as a project by the Intractable Hepato-Biliary Disease Study Group of Japan.

Conflicts of interest



  1. 1.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.PubMedGoogle Scholar
  2. 2.
    Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med. 1968;17:214–223.PubMedGoogle Scholar
  3. 3.
    Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717.PubMedGoogle Scholar
  4. 4.
    Crapper RM, Bhathal PS, Mackay IR, et al. “Acute” autoimmune hepatitis. Digestion. 1986;34:216–225.PubMedCrossRefGoogle Scholar
  5. 5.
    Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303–307.PubMedCrossRefGoogle Scholar
  6. 6.
    Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871.PubMedCrossRefGoogle Scholar
  7. 7.
    Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11:138–140.CrossRefGoogle Scholar
  8. 8.
    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.PubMedCrossRefGoogle Scholar
  9. 9.
    Yamamoto S, Maekawa Y, Imamura M, et al. Treatment of hepatitis with antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr. 1958;13:73.Google Scholar
  10. 10.
    Suzuki H, Ohta T, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double-blind trial. Asian Med J. 1983;26:423–438.Google Scholar
  11. 11.
    Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Porcell RH, Uchida T, eds. Viral hepatitis C, D and E. Amsterdam: Excerpta Medica; 1987:295–303.Google Scholar
  12. 12.
    Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–1520.PubMedCrossRefGoogle Scholar
  13. 13.
    Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res. 2001;19:31–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–669.PubMedCrossRefGoogle Scholar
  15. 15.
    Hennes EM, Zeniya M, Czaja AJ, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169–176.PubMedCrossRefGoogle Scholar
  16. 16.
    Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. (Epub ahead of print). doi: 10.1111/j.1478-3231.2011.02524.x
  17. 17.
    Finney RS, Somers GF. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol. 1958;10:613–620.PubMedCrossRefGoogle Scholar
  18. 18.
    Doll R, Hill ID, Hutton C, et al. Clinical trial of a triterpenoid liquorice compound in gastric and duodenal ulcer. Lancet II. 1962;793–796.Google Scholar
  19. 19.
    Pompei R, Flore O, Marccialis MA, et al. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979;281:689–690.PubMedCrossRefGoogle Scholar
  20. 20.
    Crance JM, Lévêque F, Biziagos E, et al. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994;23:63–76.PubMedCrossRefGoogle Scholar
  21. 21.
    van Rossum TG, Vulto AG, de Man RA, et al. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12:199–205.PubMedCrossRefGoogle Scholar
  22. 22.
    Yang BS, Ma YJ, Wang Y, et al. Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure. World J Gastroenterol. 2007;13:462–466.PubMedGoogle Scholar
  23. 23.
    Ikeda T, Abe K, Kuroda N, et al. The inhibition of apoptosis by glycyrrhizin in hepatic injury induced by injection of lipopolysaccharide/D-galactosamine in mice. Arch Histol Cytol. 2008;71:163–178.PubMedCrossRefGoogle Scholar
  24. 24.
    Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11:1077–1083.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang L, Wang B. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res. 2002;24:220.PubMedCrossRefGoogle Scholar
  26. 26.
    van Rossum TG, Vulto AG, Hop WC, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:2432–2437.PubMedCrossRefGoogle Scholar
  27. 27.
    Fujiwara K, Mochida S, Matsui A, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–657.PubMedCrossRefGoogle Scholar
  28. 28.
    Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958.PubMedCrossRefGoogle Scholar
  29. 29.
    Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–390.PubMedCrossRefGoogle Scholar
  30. 30.
    Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology. 2011;58:693–704.PubMedCrossRefGoogle Scholar
  31. 31.
    Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults. A single Japanese center experience. Hepatol Res. 2011;41:133–141.PubMedCrossRefGoogle Scholar
  32. 32.
    Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alfa 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. (Epub ahead of print). doi: 10.1016/j.dld.2011.02.014
  33. 33.
    Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset AIH. Hepatology. (Epub ahead of print). doi: 10.1002/hep.24331
  34. 34.
    Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415.PubMedCrossRefGoogle Scholar
  35. 35.
    Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5–S10.PubMedGoogle Scholar
  36. 36.
    Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res. 1993;98:69–74.PubMedGoogle Scholar
  37. 37.
    Tandon A, Tandon BN, Bhujwala RA. Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol Res. 2002;23:55–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Shin Yasui
    • 1
  • Keiichi Fujiwara
    • 1
  • Akinobu Tawada
    • 1
  • Yoshihiro Fukuda
    • 1
  • Masayuki Nakano
    • 2
  • Osamu Yokosuka
    • 1
  1. 1.Department of Medicine and Clinical Oncology, Graduate School of MedicineChiba UniversityChibaJapan
  2. 2.Department of PathologyTokyo Women’s Medical University Yachiyo Medical CenterChibaJapan

Personalised recommendations